Skip to main content
. 2021 May 20;10(5):1263. doi: 10.3390/cells10051263

Table 6.

ALT and bilirubin abnormalities noted in maraviroc phase 1 multiple-dose studies.

Phase 1 Multiple-Dose Studies [100]
ALT Maraviroc (n = 272) Placebo (n = 42)
>2 to ≤ 5× ULN 8 (2.9%) 0
>5× ULN 1 (0.4%) 0
Bilirubin—Total (n = 272) (n = 41)
>1.25 to ≤ 2.5× ULN 3 (1.1%) 0
>2.5× ULN 0 0

Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; ULN, upper limit of normal.